ARN-509 is in phase II development for castration resistant prostate cancer
Decides on the Cambridge Biomedical Campus in UK
Marks drug's first approval to treat newly diagnosed glioblastoma
Phase II results showcased at European Hematology Association meeting
BMS and AbbVie present phase II results at European Haematology Association meeting
More and more people are turning to nootropics or 'smart drugs' to enhance their cognitive ability. But what do they do, what are the risks and where do the ethical
The variety and variability of European health technology assessment criteria have created a challenging environment for pharma and a need for much greater harmonisation
Online patient network aims to help the CRO accelerate trial recruitment
Patricia Hewitt will serve private health firm as non-executive director
Connected brand experiences can drive social conversation and deeper engagement
Robert Pelzer is appointed board member at immunotherapy specialists

Webinar on how to align business intelligence globally and deploy it locally

Pharmacy group Alphega to offer free devices and tailored apps to its UK members

Complete True Life is a progressive new agency specializing in the validation of insights-led and generation of evidence-based real-world studies ...